MabThera is indicated for the treatment of previously untreated patients with stage-III-IV follicular lymphoma in combination with chemotherapy. MabThera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.

Rituximab in combination with hyaluronidase human, sold under the brand names Mabthera SC [14] and Rituxan Hycela, [31] is used to treat follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. [31]

2014年6月6日 · MabThera, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).

In the pediatric population, MabThera/Rituxan is approved in the United States, Europe and other countries for the treatment of previously untreated DLBCL, Burkitt lymphoma/leukemia or Burkitt-like lymphoma as well as GPA/MPA.

2025年3月10日 · Generic name: rituximab [ ri-TUX-i-mab ] Brand names: Riabni, Rituxan, Ruxience, Truxima Dosage form: intravenous solution (10 mg/mL; abbs 10 mg/mL; arrx 10 mg/mL; pvvr 10 mg/mL) Drug classes: Antirheumatics, CD20 monoclonal antibodies Medically reviewed by Philip Thornton, DipPharm.Last updated on Mar 10, 2025. Uses; Warnings; …

MabThera IV and MabThera SC are indicated for the treatment of: · patients with CD20 positive diffuse large B-cell non-Hodgkin’s lymphoma (DLCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy.

MabThera will provide doctors and patients using the medicine for rheumatoid arthritis, GPA, MPA or pemphigus with educational material on the risk of infection including of a rare severe infection known as progressive multifocal leukoencephalopathy (PML).

MabThera was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia. MabThera attacks these cells both directly and together with the body’s immune system.

MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vinc ristine, prednisolone) chemotherapy. 4.2 Posology and method of administration MabThera should be administered under the close supervision of an experienced healthcare

2024年7月16日 · MabThera is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy. MabThera maintenance therapy is indicated for the treatment of adult follicular lymphoma patients …